Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 11/20 | 0.38 |
| ▸ | RET | P07949 | 2/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4007014 | 0.88 | IGF1R (0.38) | IGF1RRETPLK4PAK4PIK3C3 | |
| SCHEMBL27674569 | 0.80 | ITK (0.40) | IGF1RPAK4PIK3C3 | |
| SCHEMBL343410 | 0.78 | PAK4 (0.54) | IGF1RRETPLK4PAK4PIK3C3 | |
| SCHEMBL4065934 | 0.77 | PLK4 (0.40) | IGF1RRETPLK4PAK4JAK2 | |
| SCHEMBL4308621 | 0.75 | JAK2 (0.35) | IGF1RRETPLK4PAK4JAK2 | |
| SCHEMBL22328001 | 0.74 | NPC1 (0.40) | IGF1RPIK3C3NPC1JAK2JAK3 | |
| SCHEMBL220024 | 0.74 | JAK2 (0.47) | IGF1RRETPLK4PAK4JAK2 | |
| SCHEMBL4016135 | 0.74 | IGF1R (0.64) | IGF1R | |
| SCHEMBL4913165 | 0.73 | PIK3C3 (0.45) | IGF1RPLK4PAK4PIK3C3JAK3 | |
| SCHEMBL3849950 | 0.73 | GRK6 (0.42) | IGF1RRETPLK4PAK4PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101501030-A | Pyrimidine derivatives useful in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-08-05 | — | — | CN | disclosed |
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | IGF1R 3217/4885RET 3964/4885PLK4 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.